Sign up to our newsletter Subscribe
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
Cell and Gene Therapies
Cell and gene therapies offer substantial therapeutic benefits but are expensive and often have a limited evidence base at launch. There are concerns over affordability and long-term cost-effectiveness, as well as uncertainty as to whether their value is accurately captured by current HTA methods.
No posts found